Document Detail


Beta-blockers for primary prevention in hypertension: era bygone?
MedLine Citation:
PMID:  17046433     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Beta-blockers are used commonly worldwide in clinical practice for lowering blood pressure. Most of the agents in this class are efficacious in reducing blood pressure, although they vary widely in their pharmacokinetic and pharmacodynamic properties. This variability may confer significant differences in clinical benefits associated with use of specific agents. Although commonly used in managing hypertension, the role of beta-blockers for primary prevention in uncomplicated hypertension has been controversial. Evidence from recent trials suggest relatively poor efficacy toward primary prevention and worse outcomes for certain end points, when compared with other blood pressure-lowering agents, Recently updated National Institute for Health and Clinical Excellence guidelines for England and Wales reflect this concern and have changed the indication for beta-blockers for blood pressure control from primary agents to use as an add-on agent in patients requiring multiple therapy. In this review, considering the extended debate on this topic, we discuss the general properties of beta-blockers and evidence from clinical trials supporting or refuting their use in various clinical scenarios. Newer beta-blockers have additional properties which may be beneficial. Although, whether these additional benefits will help in primary prevention is not clear.
Authors:
Gurusher S Panjrath; Franz H Messerli
Related Documents :
6285113 - An inhibitory role of beta-endorphin in central cardiovascular regulation.
3742933 - The effects of single-dose atenolol, labetalol, and propranolol on cardiac and vascular...
3194153 - Influence of smooth muscle tone and longitudinal tension on the collapsibility of immat...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Progress in cardiovascular diseases     Volume:  49     ISSN:  0033-0620     ISO Abbreviation:  Prog Cardiovasc Dis     Publication Date:    2006 Sep-Oct
Date Detail:
Created Date:  2006-10-18     Completed Date:  2006-11-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376442     Medline TA:  Prog Cardiovasc Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  76-87     Citation Subset:  AIM; IM    
Affiliation:
Department of Cardiology, St. Lukes-Roosevelt Hospital Center, Division of Cardiology, Columbia University, NY 10019, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use*
Blood Pressure / drug effects
Humans
Hypertension / physiopathology,  prevention & control*
Primary Prevention / methods*
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sodium intake and hypertension.
Next Document:  Enhanced external counterpulsation for the treatment of angina pectoris.